Well put. Given that so much sits on the accurate determination of the product's ability to correctly detect disease it seems very odd that more of a deal has not been made of the lack of clarity about the results. Calculating the sensitivity and specificity from trail results needs to be done with caution (true) but is -- in my understanding -- pretty much bread-and-butter work for a statistician. If so, why the secrecy? Why not be open and honest (like RAP management used to be) with shareholders. Something is off...
Well put. Given that so much sits on the accurate determination...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #